View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 9, 2020

Daiichi Sankyo to develop Nafamostat inhalation therapy for Covid-19

Japanese pharmaceutical company Daiichi Sankyo has signed a a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.

Japanese pharmaceutical company Daiichi Sankyo has signed a basic agreement with the University of Tokyo, Nichi-Iko Pharmaceutical and RIKEN for the research and development (R&D) of a Nafamostat inhalation formulation to treat Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Nafamostat is an injectable drug indicated in Japan for the treatment for acute pancreatitis and disseminated intravascular coagulation. According to the data available so far, the drug is adequately safe.

During the first stage of Covid-19 infection, the outer enveloped of SARS-CoV-2 fuses with the host cell surface membrane. Researchers at the University of Tokyo and others have found that Nafamostat could prevent this fusion and block viral entry.

In a statement, the partners said: “Through the partnership, the University of Tokyo, RIKEN, Nichi-Iko and Daiichi Sankyo hope to provide patients with a new treatment option for COVID-19 as early as possible.”

For drug discovery and medical technology platforms, RIKEN introduced a programme to optimise the medical seeds from basic research at the company and universities for the drug discovery process at pharmaceutical firms and in clinical practice.

As part of this Covid-19-focused R&D partnership, RIKEN will provide support via advanced technologies.

Meanwhile, Nichi-Iko holds the marketing authorisation for nafamostat mesilate under the brand name Futhan. The company will provide data obtained over the past years and also deliver the API for collaborative R&D.

Daiichi Sankyo will be responsible for R&D on the Nafamostat inhalation formulation. The company will leverage the technology used for the development of its anti-influenza virus product, Inavir.

Non-clinical studies of the potential Covid-19 therapy are expected to begin next month, with plans for advancing into clinical trials by March next year following discussions with authorities.

Last month, the Japanese Ministry of Health, Labour and Welfare (MHLW) granted authorisation under exceptional approval pathway for the use of Gilead Sciences’ antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology